AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01124292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usability assessment
Description: Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions.
Study NCT02555124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 5 mg
Description: Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
Study NCT02555124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 20 mg
Description: Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
Study NCT02555124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922, 40 mg
Description: Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
Study NCT02555124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
Study NCT02332564 — intervention group
Intervention type: OTHER
Intervention: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
Description: Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
Study NCT01810705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
Study NCT00574249 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
Study NCT00574249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol/Betamethasone Ointment
Description: Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Study NCT00574249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (vehicle ointment)
Description: Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Study NCT03070405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Single oral dose on the first day of each period
Study NCT03070405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Single oral dose on the first day of each period
Study NCT03070405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid Ca granule 5.28 g
Description: Twice daily oral administration from the first day of each period to the seventh dose
Study NCT04944303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
Study NCT04944303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
Study NCT04944303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equal doseage of normal saline was injected to reverse the NMB.
Study NCT04944303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Equal doseage of normal saline was injected to reverse the NMB.
Study NCT02175381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
Study NCT02175381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
Study NCT02322450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001
Study NCT02322450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00955981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout
Study NCT00955981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04559035 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal lavage
Description: Twice daily nasal lavage.
Study NCT00810017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
Study NCT00810017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
Study NCT03042754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: XpertMTB/RIF
Study NCT00664456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: 3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
Study NCT01288092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study NCT02110030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Description: The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain.
Study NCT02110030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Currents
Description: The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain).
Study NCT03541109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
Study NCT03526198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Force plate
Description: Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
Study NCT00231283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
Description: CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
Study NCT03057223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific titanium plates
Description: 3D-printed patient-specific titanium plates will be used in patients.
Study NCT00394134 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: Interviews to describe the sun exposure and sun protection practices of patients and their children.
Study NCT01094782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects receive 6 acupuncture treatments for neck or back pain.
Study NCT01094782 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Subjects receive 6 sham acupuncture treatments for neck or back pain.
Study NCT02253121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
Study NCT02253121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sliding scale insulin
Description: Sliding scale insulin with short acting insulin based on current glucose levels
Study NCT02253121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sliding scale insulin
Description: Sliding scale insulin with short acting insulin based on current glucose levels
Study NCT01902355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified Seldinger technique
Description: modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
Study NCT01902355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique
Description: The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
Study NCT03776071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzastaurin Hydrochloride
Description: mg
Study NCT03776071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mg
Study NCT03776071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: mg/m\^2
Study NCT03776071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: mg/m\^2
Study NCT03776071 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Gy
Study NCT03776071 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Gy
Study NCT02904551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
Study NCT02904551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral prophylaxis
Description: Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
Study NCT03242642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Description: mitral valve replacement
Study NCT03242642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Description: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
Study NCT02960555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV
Study NCT02960555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03781583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 1
Description: First version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds.
Study NCT03781583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 2
Description: Second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones.
Study NCT03781583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 3
Description: Third iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software.
Study NCT03781583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHMD version 4
Description: Fourth iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software.
Study NCT04424511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
Study NCT04424511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
Study NCT04424511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
Study NCT01866267 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
Study NCT00435019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: s.c. injection, once or twice daily.
Study NCT00435019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: s.c. injection, once or twice daily.
Study NCT00435019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: s.c. injection, at main meals.
Study NCT00311103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific clinical care program
Description: The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
Study NCT03909854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mode of mechanical ventilation
Description: Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
Study NCT03679169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatosplenectomy
Description: standard or radical anterograde modularpancreatosplenectomy
Study NCT03679169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreatosplenectomy
Description: standard or radical anterograde modularpancreatosplenectomy
Study NCT02222441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib alone
Description: A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
Study NCT02222441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Modafinil
Description: For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
Study NCT02222441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib plus pioglitazone
Description: For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
Study NCT00083720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
Study NCT01324570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system
Description: Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
Study NCT01819753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
Study NCT04536870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Ultrasound of heart
Study NCT04536870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG screening
Description: Single lead ECG screening twice daily for two weeks
Study NCT04536870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG Screening
Description: 12-lead ECG screening
Study NCT00664456 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy（iodine I 125）
Description: Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
Study NCT00816621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC for Children Adopted Internationally
Description: Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
Study NCT00816621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DEF for Children Adopted Internationally
Description: Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
Study NCT04266613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TruGraf® Testing
Description: 5 mL collection PAXgene blood sample
Study NCT02589418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
Study NCT02589418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Acupuncture
Description: Needle insertion and manipulation at 4 non-acupoints
Study NCT02589418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Acupuncture
Description: Control intervention: No needle insertion and manipulation
Study NCT00962221 — intervention group
Intervention type: PROCEDURE
Intervention: laboratory analysis
Description: laboratory analysis
Study NCT03966534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood diversion
Description: Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
Study NCT04145609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic
Description: Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach